TBPH vs AURA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
TBPH Captures Institutional Edge (3โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Theravance Biopharma, Inc. (TBPH) driven by superior Valuation, Growth & Margin, Options & Structure while AURA counters with relative strength in Momentum & Technical. Fundamentally, TBPH trades at 13.4x Forward P/E with 8.9% operating margin (-20.9% YoY revenue) versus AURA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, TBPH sits in UNCLASSIFIED (16th %ile IV; Dealer Gamma Walls on Pro) against AURA sits in CONSOLIDATION (22nd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | TBPH | AURA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $884.2M | $728.6M | Larger Scale | TBPH |
| Trailing P/E Ratio Valuation | 16.4x | N/M | Lower Multiple | TBPH |
| Forward P/E Ratio Valuation | 13.4x | N/M | Lower Multiple | TBPH |
| Revenue Growth (YoY) Growth | -20.9% | +0.0% | Higher Growth | AURA |
| Operating Margin (TTM) Profitability | 8.9% | 0.0% | Higher Margin | TBPH |
| Net Profit Margin Profitability | 51.6% | 0.0% | Higher Margin | TBPH |
| Return on Equity (ROE) Capital Efficiency | 20.9% | -61.7% | Higher ROE | TBPH |
| 52-Week Range Position Momentum | 50% ($13โ$21) | 52% ($5โ$10) | Stronger Trend | AURA |
| Beta / 30D Volatility Risk Regime | 0.48ฮฒ ยท 2% Vol | 0.92ฮฒ ยท 75% Vol | Lower Realized Risk | TBPH |
| Unified Institutional Score Composite Signal | 54.9 / 100 (HOLD) | 28.8 / 100 (SELL) | Higher Composite | TBPH |